Michael W. Bonney
United States of America
Michael W. Bonney was elected to our Board of Directors on April 14, 2015 and is a member of the Audit Committee. Mr. Bonney served as Chief Executive Officer and a member of the Board of Directors of Cubist Pharmaceuticals Inc. (Cubist) (a subsidiary of Merck & Co., Inc. as of January 2015) from June 2003 until his retirement on December 31, 2014. From January 2002 to June 2003, Mr. Bonney served as Cubist’s President and Chief Operating Officer, and from 1995 to 2001, he held various positions of increasing responsibility at Biogen, Inc., including Vice President, Sales and Marketing from 1999 to 2001. Prior to joining Biogen, Mr. Bonney held various positions of increasing responsibility in sales, marketing and strategic planning at Zeneca Pharmaceuticals, finishing his eleven-year career there by serving as National Business Director. Since 2014, Mr. Bonney has been a director of Alynylam Pharmaceuticals, Inc., where he serves on the audit committee. He is also a trustee of the Tekla complex of life sciences and healthcare dedicated funds, where he serves on the valuation committee and chairs the governance committee and the nominating committee. He also chairs the board of trustees of Bates College. Mr. Bonney was a Director of NPS Pharmaceuticals, Inc. from 2005 until its sale to Shire plc in February 2015, where he was a member of the audit and compensation committees and chaired the governance committee. He was a member of the Pharmaceutical Research and Manufacturers of America (PhRMA) from 2009 – 2014 and the Biotechnology Industry Organization (BIO), a non-profit biotechnology trade organization, from 2004 – 2009. Mr. Bonney received a B.A. in Economics from Bates College.